Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Income from Continuing Operations (2021 - 2025)

Historic Income from Continuing Operations for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to -$1.7 million.

  • InMed Pharmaceuticals' Income from Continuing Operations fell 292.22% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.2 million, marking a year-over-year decrease of 2058.41%. This contributed to the annual value of -$8.2 million for FY2025, which is 633.94% down from last year.
  • As of Q3 2025, InMed Pharmaceuticals' Income from Continuing Operations stood at -$1.7 million, which was down 292.22% from -$1.8 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Income from Continuing Operations registered a high of -$336591.0 during Q2 2023, and its lowest value of -$7.9 million during Q2 2022.
  • Over the past 5 years, InMed Pharmaceuticals' median Income from Continuing Operations value was -$2.1 million (recorded in 2022), while the average stood at -$2.6 million.
  • In the last 5 years, InMed Pharmaceuticals' Income from Continuing Operations soared by 9572.31% in 2023 and then tumbled by 47356.58% in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Income from Continuing Operations stood at -$4.3 million in 2021, then surged by 51.01% to -$2.1 million in 2022, then increased by 29.55% to -$1.5 million in 2023, then tumbled by 74.2% to -$2.6 million in 2024, then soared by 32.94% to -$1.7 million in 2025.
  • Its Income from Continuing Operations stands at -$1.7 million for Q3 2025, versus -$1.8 million for Q2 2025 and -$2.1 million for Q1 2025.